I
n ST-segment elevation myocardial infarction (STEMI), extensive necrosis and poor left ventricular (LV) function predicts an impaired prognosis. 1, 2 To salvage myocardium at risk, the cornerstone of therapy is to promptly restore culprit vessel flow, preferably by primary percutaneous coronary intervention (pPCI). 3 However, abrupt restoration of blood flow may itself cause detrimental myocardial reperfusion injury, which possibly explains why a substantial number of patients with STEMI end up with low salvage, compromised LV function, and heart failure. 4 
Clinical Perspective on p 662
Local and remote ischemic conditioning (rIC) are potent activators of innate protection against ischemia-reperfusion injury. The underlying mechanisms behind these cardioprotective strategies are not fully clarified. Common pathways involve modification of mitochondrial function by opening ATP-sensitive potassium channels and closing mitochondrial permeability transition pores. 5 Recently, we demonstrated that rIC by repeated cycles of nonlethal upper-limb ischemia applied during ambulance transfer in patients with evolving STEMI increased myocardial salvage. 6 The benefit was most pronounced in patients with extensive myocardium at risk. It is of major clinical importance to assess the effects of rIC on the function of the LV. Usually, conventional 2D and 3D echocardiographic imaging are used, yet recent data show that global strain in the long-axis plane assessed by speckle-tracking deformation imaging may be superior to conventional echocardiography in estimating LV function and infarct size. [7] [8] [9] [10] Conventional and speckle-tracking-derived indices are retrieved from the same echocardiographic data sets and are not independent.
Therefore, as a supplementary independent method, LV function was assessed by myocardial perfusion imaging (MPI) in addition to echocardiography.
Thus, the aim of the present substudy was to evaluate the effect of rIC on LV function and remodeling by comprehensive echocardiography and MPI within 24 hours after pPCI and after 30 days follow-up. The effect of rIC was analyzed in relation to the size of the myocardial area at risk (AAR), infarct location, and target vessel patency.
Methods

Study Population
The rIC in STEMI trial was a single-center, randomized controlled trial that compared prehospital treatment with cycles of upper-limb ischemia as adjunctive to pPCI with standard pPCI in patients with acute STEMI. Patient inclusion, randomization, and intervention have been previously published in detail. 6 In brief, patients were included from February 2007 to October 2008. Criteria for inclusion were as follows: (1) symptoms consistent with myocardial infarction lasting between 30 minutes and 12 hours, (2) ST-segment elevation of Ͼ0.1 mV in 2 or more contiguous leads, and (3) age Ͼ18 years. Patients were excluded from analysis on the basis of the following criteria: (1) previous coronary bypass surgery, (2) left bundle branch block, (3) treatment with fibrinolysis within the previous 30 days, (4) left main stenosis requiring coronary artery bypass surgery, (5) cardiogenic shock, and (6) previous myocardial infarction. During ambulance transfer, patients given a tentative diagnosis of STEMI were randomized to pPCI revascularization (pPCI alone [control group]) or pPCI revascularization plus remote conditioning (rICϩpPCI [intervention group]) through intermittent arm ischemia. Arm ischemia was obtained by 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to 200 mm Hg or 25 mm Hg above systolic blood pressure in case this was Ͼ175 mm Hg. Before coronary intervention, patients received treatment with aspirin 300 mg, clopidogrel 600 mg, and unfractionated heparin 10 000 IU. Abciximab was given when not contraindicated.
The study protocol complied with the Declaration of Helsinki and was approved by the local ethics committee. All participants gave informed consent.
Echocardiography
We used a commercially available ultrasound system (Vivid 7; GE Healthcare; Horten, Norway) with a 3.5-MHz phased array transducer (M4S). The first echocardiography was performed at a median of 13 hours (Q1 to Q3; 8 hours to 18 hours) after pPCI. The observer was blinded to the treatment allocation. Patients were reexamined after 30 days. Examinations were made by 2 observers (K.M., N.H.A.). Data were stored digitally and analyzed off line by a single investigator (K.M.) blinded to clinical data, using dedicated software (Echopach PC [software only] 7.0.0 [GE Healthcare; Milwaukee, Wis], including Tomtec 4D LV-Function [Tomtec Imaging Systems; Unterschleissheim, Germany]). Two-dimensional ejection fraction (EF) measurements were based on end-systolic and end-diastolic LV volumes, using the biplane method of discs. 11 Volume data are averages of 3 measurements.
Systolic strain was obtained from frame-by-frame tracking of speckle patterns throughout the left-sided myocardium in standard 2D cine-loops, with frame rates between 50 and 90 1/s. 12, 13 Timing of systole was determined from aortic valve opening and closure. The speckle area of interest was manually adjusted for optimal tracking results. Segments with unacceptably low tracking quality due to poor image acquisition or artifacts were excluded. Global longitudinal systolic strain (GLS) 14 was calculated by the software as the average longitudinal systolic strain of 17 myocardial segments 15 at the time in systole when the value peaked. The software allowed calculation of GLS only when tracking quality was adequate in at least 5 of 6 segments in each apical view.
Full-volume 3D data sets were obtained using a 3.5-MHz matrix array transducer (3V). Optimal transducer position and angle was adjusted using the 3-plane imaging mode. When, in the respiratory cycle, optimal endocardium delineation was achieved, a full-volume electrocardiography-gated data set through 4 cardiac cycles was sampled during apnea. With use of the Tomtec 4D LV-Function software package, end-diastolic and end-systolic endocardial tracings were drawn manually in the 3 apical standard image planes. The software then tracked the surface in each frame throughout the cardiac cycle. The surface delineation was adjusted manually as needed. LV EF was calculated from end-diastolic and end-systolic estimates of these virtual LV-cavity casts.
Intraobserver variability was assessed from readings on 25 randomly selected patients. The intraobserver repeatability analysis showed a mean absolute difference of 0.3% (95% CI, Ϫ0.2% to 0.7%) for GLS, Ϫ0.02 (95% CI, Ϫ0.04; 0.01) for Simpsons 2D EF, and Ϫ0.02 (Ϫ0.03 to 0.01) for 3D EF. Coefficients of repeatability (1.96 SD on differences) on a relative scale were 11% (95% CI, 8% to 15%) for GLS, 23% (95% CI, 18% to 32%) for 2D EF, and 9% (95% CI, 7% to 13%) for 3D EF.
Single-Photon Emission CT
In the main study, salvage index (the proportion of AAR salvaged by treatment) was the primary end point. Before pPCI, 99m Tc-sestamibi was injected, and myocardial AAR was measured by MPI within 8 hours after pPCI. At the 30-day follow-up visit, patients received 700Ϯ10% MBq 99m Tc-sestamibi IV after 15 minutes bed rest. Single-photon emission CT (SPECT) was performed after 1 hour using a high-resolution, parallel-hole collimator dual-headed rotating gamma camera (ADAC; Forte; Milpitas, Calif) with no scatter or attenuation correction. Images were gated at 8 frames per cardiac cycle. Accumulated radiation dose of the 2 MPI examinations were Ϸ12 mSv, equaling 120 chest radiographs. This radiation dose corresponds to an estimated 0.1 absolute percent increase in lifetime risk of dying from a malignancy added to the background risk equaling 21%. 16 Data were analyzed independently by 2 experienced nuclear cardiology readers. Images were analyzed with the commercially available automatic quantitative perfusion SPECT and quantitative gated SPECT programs (QPS and QGS) (Cedars-Sinai Medical Center; Los Angeles, Calif). 17, 18 In case of failure of the automatic algorithm, tools for masking extracardiac activity and defining the valve plane and the apex of the LV manually were used. Infarct size was calculated as the area of the LV containing counts lower than a mean normal limit for pixels, using a sex-specific MIBIMIBI rest database as reference. If the interreader difference in defect size exceeded 3%, a consensus reading was obtained from the 2 readers. Volumes of LV cavities at end systole and end diastole were assessed as described. 19 
Statistics
The sample size was given by the main study. However, in planning this echocardiographic study, we considered whether GLS could be achieved in an adequate number to reach acceptable statistical power. An absolute difference in GLS of 2% (Ϸabsolute difference in EF of 0.05) between treatment groups was regarded as a clinically relevant improvement. Based on a mean GLS of Ϫ14.6Ϯ4.6% in patients with STEMI, with a risk of type 1 error (␣ϭ0.05), we estimated that a power (1Ϫ␤) of 0.80 requires 85 participants in each group, and a power of 0.90 requires 110 participants in each group.
Continuous data conforming to a normal distribution are presented as meanϮSD, nonnormal continuous data are presented as median including first (Q1) and third (Q3) quartiles, and categorical data are presented as absolute values with percentages. Histograms and Q-Q plots were used to check continuous values for normality. Comparison of continuous variables between treatment groups was done by unpaired t test and by Mann-Whitney U test in variables that were not normally distributed. Categorical data were compared using 2 test or Fisher exact test when tabled numbers were Ͻ10. Reproducibility and agreement between echocardiographic and SPECT volume data were compared by the Bland-Altman method. 20 We used a standard statistical software package (STATA/IC 10.1; StataCorp LP; College Station, Tex).
Results
Study Population and Patient Characteristics
Details on randomization, reason for exclusion after prehospital randomization, and completeness of data are outlined in Figure 1 . Of 333 patients enrolled during transfer to pPCI, 166 were assigned to rICϩpPCI and 167 to pPCI alone. Eighty-two (40 rICϩpPCI and 42 pPCI alone) were excluded from analysis because they did not fulfill the study criteria. Nine patients (3 rICϩpPCI and 6 pPCI alone) had neither day-1 nor 1-month echocardiography. Thus, the study population comprised 242 patients (123 rICϩpPCI and 119 pPCI alone) completing the day-1, 30-day, or both echocardiography. Baseline characteristics were similar except for hypertension (Table 1) .
Total Study Cohort
Myocardial AARs were similar in treatment groups (rICϩpPCI, 26Ϯ14% of LV [nϭ81]; pPCI alone, 27Ϯ16% of LV [nϭ76]; Pϭ0.9). Overall, LV function recovered significantly from day 1 (EF-2D, 0.50Ϯ0.10; GLS, Ϫ15.3Ϯ3.8%) to 1 month (EF-2D, 0.53Ϯ0.10; Pϭ0.0001; GLS, Ϫ16.9Ϯ3.4%; PϽ0.0001). No significant differences were observed between treatment groups overall ( 
9).
In patients with LAD-related STEMI, EF-2D on day 1 was 0.51Ϯ0.11 in rICϩpPCI patients versus 0.46Ϯ0.11 in pPCI-alone patients (Pϭ0.03). GLS and LV volumes did not differ. After 1 month, patients with LAD-related STEMI persistently had a higher EF (2D echocardiography and gated SPECT) and a borderline higher GLS (more negative) in the rICϩpPCI versus pPCI-alone groups ( Figure 2 , Table 3 ). Besides better LV function, smaller LV volumes (reaching statistical significance by gated SPECT) were observed with rIC, indicating less adverse remodeling (Table 3) . Furthermore, rICϩpPCI-treated patients (nϭ42) developed smaller infarcts of 7% of LV (Q1 to Q3, 1% to 16%) versus 16% of LV (Q1 to Q3, 4% to 25%) in the control group (nϭ44) (Pϭ0.01). For patients with STEMI due to culprit vessels located outside the LAD territory, no difference was observed between treatment groups with regard to EF (2D, 3D, gated SPECT), GLS, and LV volumes on day 1 and after 1 month.
Impact of Remote Conditioning in Relation to Preprocedural Vessel Patency
One hundred thirty-seven patients had occluded culprit vessels (thrombolysis in myocardial infarction [TIMI] flow grade 0 to 1) on arrival at the catheterization laboratory. In the total population, EF-2D on day 1 was 0.49Ϯ0.10 in patients with occluded vessels versus 0.51Ϯ0.11 in patients with patent vessels (Pϭ0.08) on arrival. Corresponding values for GLS were Ϫ14.2Ϯ3.6% versus Ϫ16.0Ϯ4.3% (PϽ0.002). On day 30, EF-2D was 0.51Ϯ0.08 versus 0.56Ϯ0.09 (Pϭ0.0001), and GLS was Ϫ16.5Ϯ3.1% versus Ϫ17.9Ϯ3.8% (Pϭ0.01) in patients with occluded and patent vessels, respectively. There was no difference in AAR between the treatment groups (rICϩpPCI AAR, 34Ϯ11% of LV [nϭ45]; pPCI alone, 34Ϯ13% of LV [nϭ45]), and no difference was found in infarct size (rICϩpPCI, 9% of LV; Q1 to Q3, 3% to 18% [nϭ59]; pPCI alone, 13% of LV; Q1 to Q, 34% to 24% [nϭ65]; Pϭ0.11). On day 30, rIC did not significantly affect LV function either in patients with patent target vessel or in patients with occluded target vessels on arrival (Table 3) .
Comparison of EF and Volumes by Gated SPECT and Echocardiography
SPECT yielded higher volume estimates than echocardiography. Volume over-and underestimation were of the same relative size for systolic and diastolic volumes, so there was no significant bias between EF estimates by SPECT and echocardiography (EF-2D versus SPECT) (bias, 0; 95% CI, Ϫ0.02 to 0.01; lower limit of agreement, Ϫ0.15; upper limit of agreement, 0.15); 3D echocardiography versus SPECT (bias, 0.01; 95% CI, Ϫ0.01 to 0.02; lower limit of agreement, Ϫ0.14; upper limit of agreement, 0.16).
Method Feasibility
The quality of the obtained echocardiographic recordings did not allow complete assessment of all indices in every patient. The patients completing each examination along with the number of patients with each index available are outlined in Table 2 . From these numbers, the feasibility was calculated for EF-2D as 0.94 and 0.95, for EF-3D as 0.77 and 0.81, and for GLS as 0.84 and 0.88 on day 1 and day 30, respectively.
Discussion
The results of the present study demonstrate that patients with extensive AAR Ͼ35% of LV gain substantial benefit from rIC in terms of a persistent preservation of LV function. Moreover, in the subset of patients with LAD infarct, those treated with rICϩpPCI had preserved LV myocardial performance acutely and persistently after 1 month, and MPI demonstrated significantly decreased LV volumes, indicating less adverse remodeling after rIC. The findings were consistent by 2 independent imaging modalities. Besides patients with large AAR, patients with anterior infarction constituted an additional high-risk population. 2, 21, 22 Hence, rIC as adjunctive to pPCI is of potential clinical benefit, particularly in high-risk patients.
Overall, the present study population had a well-preserved residual LV function (EF-2D day 30, 0.54Ϯ0.09). The majority (69%) of patients had an EF-2D Ն0.50, and only 8% experienced a critically low EF-2D Յ0.40 after 30 days, reflecting best medical practice with respect to prehospital diagnostics and rapid hospital admission, optimal revascularization techniques, and most advantageous medical therapy. This encouraging outcome challenges the possibility to demonstrate an overall benefit on LV function by a strategy aiming to attenuate reperfusion injury. Previous clinical myocardial infarction-reperfusion studies in unselected STEMI populations have shown neutral results on LV function. 23, 24 Even a large-scale metaanalysis (14 355 patients) that compared thrombolytic reperfusion therapy with conservative treatment failed to demonstrate more than a tendency toward LV improvement. 25 Conversely, in small-sized studies with fewer than 100 selected patients with STEMI caused by LAD or right coronary artery occlusion, improvement of LV function has been demonstrated by modification of reperfusion with nicorandil 26 or postconditioning. 27 In addition to assessment of LV function by traditional EF measurement, we studied the longitudinal systolic function by 2D speckle-tracking strain imaging. Longitudinal systolic function was affected similarly after STEMI in our study compared with previous investigations. 14, 28 Consistent with the results from the traditional LV measurements, GLS increased by rIC in patients with extensive myocardium at risk, and in patients with LAD-STEMI, GLS was borderline significantly higher. Speckle-tracking strain has been validated in phantoms and in vivo. 29 -31 GLS by speckle tracking correlates with infarct size 8 -10 and has been proposed to be Although echocardiographic recordings were obtained under optimal conditions with the patients carefully positioned on a dedicated ultrasound table, both speckle-tracking and real-time 3D echocardiography were hampered by a limited feasibility. The consequent loss of data may explain the loss of statistical power by GLS and 3D EF compared to 2D LV measurements in the subset of patients with LAD-STEMI. Thus, the precision merits of GLS and 3D EF as markers of LV function as confirmed from lower coefficients of repeatability in this study may be lost by a reduced feasibility.
Limitations
Our main results were found in subgroups, increasing the likelihood that these effects have arisen by chance as a result of multiple testing. One therefore should be careful in the interpretation, and the corresponding P values should be taken with caution. From a statistical viewpoint, a significance level of PϽ0.05 is a liberal threshold that may have inflated type I error in this setting. However, it must be emphasized that the subgroups consisted of high-risk patients prone to develop large infarcts, in which it is plausible that treatment effects, if any, should be most pronounced and, therefore, easier to detect.
Data on LV function before randomization were not available because of the unpredictable nature of STEMI. Therefore, we cannot rule out that a difference in LV function might have existed before the index infarction. Theoretically, such difference could have influenced our results.
Conclusion
Although data on LV function obtained from the whole study cohort revealed no significant differences, rIC during transfer to primary angioplasty modestly improved LV function and remodeling in patients at risk of large myocardial infarcts. Future large-scale studies are needed to confirm these findings and to clarify whether this effect can be translated into improved clinical outcome.
CLINICAL PERSPECTIVE
Survivors of myocardial infarction with compromised left ventricular (LV) function are prone to experience adverse events, such as ventricular arrhythmia, heart failure, and death. A major target for primary coronary revascularization in patients with ST-segment elevation myocardial infarction is to diminish post-myocardial infarction LV dysfunction. Previously, we have found adjunctive treatment by remote ischemic conditioning (ie, the application of intermittent peripheral limb ischemia during transport of patients to invasive treatment) to increase myocardial salvage. In the present study, we evaluated whether remote ischemic conditioning mediated a clinically relevant improvement of LV function using 2 independent methods: echocardiography and myocardial perfusion imaging. In the total cohort, there was no significant effect, but in patients at a high risk of developing a large infarction (ie, patients with large myocardial area at risk and those with left anterior descending occlusion), remote conditioning improved LV ejection fraction and remodeling. Before wide clinical implementation of this low-cost and simple cardioprotective modality, trials confirming our findings as well as data on hard clinical outcomes are needed.
